Emergent Biosolutions doubles size of vaccine manufacturing operation in Bayview - Technical.ly Baltimore

Sciences

May 12, 2017 8:04 am

Emergent Biosolutions doubles size of vaccine manufacturing operation in Bayview

The facility has produced Ebola and Zika treatments during recent outbreaks.

Emergent Biosolutions' Bayview facility.

(Courtesy photo)

The U.S. Health and Human Services Department designates three centers to develop and manufacture vaccines that can respond to public health threats.

One of them is in Baltimore, and it just doubled in size.

The Emergent Biosolutions facility, which is in Bayview, is now 112,000 square feet.

Equipped with lab, manufacturing and offices, it’s designed so that Emergent can produce vaccines and treatments quickly when ordered.

Since the partnership to make the site a Center for Innovation in Advanced Development and Manufacturing was inked in 2012, the facility has already completed orders to develop therapeutics during the Ebola crisis, as well as a Zika vaccine candidate.

Emergent, which is based in Gaithersburg, is known in biopharmaceutical circles for developing the only anthrax vaccine that was approved by the FDA. The company also uses the Baltimore facility to manufacture its own candidate products.

The company is another sign of the effort to knit Maryland’s biotech community between Baltimore and I-270 more closely together. Advances in vaccines are being developed in the city at University of Maryland-Baltimore and Johns Hopkins University, and the companies that spin out from the research that goes on at those institutions. The facility’s expansion shows the products can be made here, as well.

Advertisement

Along with providing medical needs, Emergent will also create jobs in Baltimore. That was a focus of remarks by officials at a ribbon-cutting on Wednesday.

“They are at the forefront of innovation, and represent everything we want in a Baltimore-area company,” said City Council President Bernard C. “Jack” Young, according to prepared remarks. “Emergent also continues to emphasize local hiring, which I have fought hard to promote so we can increase job opportunities and put our city to work.”

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

The acquisition deal for Columbia-based Osiris Therapeutics is now complete

Baltimore’s Paragon Bioservices to be acquired by drug manufacturer Catalent for $1.2B

Paragon Bioservices expands, plans hires with new manufacturing facility

SPONSORED

Baltimore

How SmartLogic accelerated these startups’ product growth trajectories

Philadelphia, PA

Orthly

Full-Stack Javascript Engineer

Apply Now
Baltimore, MD 21201

14 West

Chief of Staff

Apply Now
Baltimore, MD

SmartLogic

Product Designer

Apply Now

Columbia-based Osiris Therapeutics to be acquired in $660M deal

Partnering with French firm, Early Charm Ventures looks to European market

Gliknik receives $15M payment from Pfizer after reaching clinical milestone

SPONSORED

Baltimore

This fast-growing SaaS company aims to be a force for change in the energy industry

Baltimore

Technically Media

Technical.ly Baltimore Contributing Reporter (Contract or Freelance)

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now
Baltimore, MD 21201

14 West

Application Security Engineer (Pen Tester)

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!